Recombinant Protein CDMO Services & Complex Biologics Manufacturing Support
Recombinant proteins cover one of the widest ranges in biologics manufacturing.
Some proteins express cleanly, purify predictably, and remain stable with a straightforward formulation. Others create serious development challenges. They misfold, aggregate, clip, oxidize, bind surfaces, lose activity, require cofactors, need specific glycosylation, form multimers, resist purification, degrade during storage, or behave differently after scale-up.
CDMO Network supports recombinant protein and complex biologics programs across discovery, research-grade supply, preclinical development, GMP clinical manufacturing, commercial production, diagnostic reagent supply, industrial biologics, food and nutrition proteins, and specialty biological materials.
Our support includes host selection, construct design, expression screening, cell line development, strain engineering, microbial fermentation, mammalian cell culture, yeast expression, insect-cell expression, cell-free expression, upstream process development, downstream purification, refolding, activity testing, potency assays, impurity profiling, formulation, stability, sterile fill-finish, tech transfer, scale-up, and commercial supply planning.
This modality group includes therapeutic proteins, recombinant enzymes, cytokines, growth factors, hormones, blood factors, plasma proteins, glycoproteins, fusion proteins, peptides, modified proteins, long-acting proteins, difficult-to-express proteins, membrane proteins, disulfide-rich proteins, aggregation-prone proteins, protease-sensitive proteins, lysosomal enzymes, diagnostic proteins, scaffold proteins, recombinant antigens, viral antigens, protein complexes, and multimeric proteins.
The manufacturing route starts with the protein’s structure, function, expression system, intended use, and quality target.
A cytokine does not route like a diagnostic antigen. A lysosomal enzyme does not route like a microbial industrial enzyme. A growth factor does not route like a multimeric antigen. A membrane protein does not route like a secreted protein. A glycoprotein does not route like a small non-glycosylated protein.
The CDMO route has to match the protein, not the category label.
Recombinant protein programs start with expression fit
Expression system selection shapes the entire program.
CHO, HEK293, E. coli, Pichia, Saccharomyces, Bacillus, filamentous fungi, insect cells, stable cell lines, transient expression systems, cell-free systems, and engineered hosts each create different manufacturing advantages and constraints.
CHO supports many complex therapeutic proteins and glycoproteins. HEK293 supports transient expression, early development, and some human-like processing needs. E. coli supports speed, cost efficiency, plasmids, enzymes, fragments, and non-glycosylated proteins, but folding and endotoxin require attention. Yeast systems support scalable eukaryotic expression and secretion. Insect cells support baculovirus expression, viral antigens, VLP-related proteins, and complex assemblies. Cell-free systems support rapid production and difficult expression cases.
CDMO Network routes recombinant protein programs by expression fit, not convenience.
Our network supports small research-scale expression, screening-scale production, pilot fermentation, GMP clinical batches, large-scale mammalian culture, microbial manufacturing, commercial protein supply, and specialty systems for difficult proteins.
A strong expression route produces the correct protein form at the quality and scale the program needs.
Therapeutic proteins and complex biologics
Therapeutic protein programs require strong control over structure, activity, purity, stability, and clinical-use quality.
This category includes cytokines, growth factors, hormones, blood factors, plasma protein analogs, lysosomal enzymes, fusion proteins, Fc-fusions, modified proteins, PEGylated proteins, long-acting proteins, enzymes, receptor proteins, immunomodulatory proteins, and other functional biologics.
Our support includes expression-system selection, cell line development, strain development, upstream process development, downstream purification, impurity clearance, potency assay development, activity assays, glycan analysis where relevant, formulation, stability, GMP manufacturing, sterile fill-finish, quality systems, regulatory CMC, and tech transfer.
Therapeutic proteins need more than production yield.
A cytokine needs biological activity and impurity control. A growth factor needs potency in the intended biological system. A lysosomal enzyme can require glycosylation control and uptake-related function. A blood factor or coagulation-related protein needs activity, purity, and stability. A modified protein needs control of the modification and the base protein. A fusion protein needs both domains to remain functional.
The process, analytics, and formulation must protect the biological function that makes the product therapeutic.
Enzymes, cytokines, growth factors, and active proteins
Many recombinant protein programs center on biological activity.
Enzymes require activity, specific activity, substrate performance, cofactor control, thermal stability, pH profile, matrix compatibility, and storage behavior. Cytokines and growth factors require potency, receptor binding, biological activity, purity, and stability. Hormones and signaling proteins require identity, correct structure, activity, and dose-relevant consistency.
CDMO Network offers recombinant enzyme production, cytokine manufacturing, growth factor production, hormone protein support, and specialty active protein manufacturing across microbial, mammalian, yeast, insect, and cell-free systems.
Our support includes activity assay development, potency testing, specific activity testing, kinetic review, impurity profiling, endotoxin control where relevant, refolding support, formulation, lyophilization, and stability testing.
Activity-based products need methods that reflect their use.
A protein can look correct by mass and still fail biologically. Activity testing, potency assays, and application-relevant functional methods show whether the product still performs.
That evidence drives release, stability, comparability, and customer confidence.
Difficult-to-express and unstable proteins
Some recombinant proteins resist standard development.
Difficult proteins can fail through low expression, poor secretion, misfolding, inclusion bodies, aggregation, proteolysis, incorrect disulfide pairing, membrane association, instability, toxicity to host cells, or difficult downstream recovery.
CDMO Network supports difficult-to-express protein programs through host screening, construct optimization, codon strategy, fusion tags, secretion signal evaluation, chaperone strategies, refolding workflows, periplasmic expression, alternative hosts, cell-free expression, fermentation condition screening, purification redesign, and formulation screening.
This support covers membrane proteins, disulfide-rich proteins, aggregation-prone proteins, protease-sensitive proteins, multimeric proteins, secreted proteins, low-solubility proteins, and complex protein assemblies.
A difficult protein needs disciplined options.
Changing the host, construct, induction strategy, temperature, secretion route, purification pH, buffer system, or formulation can change the outcome. The work needs structured troubleshooting rather than repeated production attempts that recreate the same failure.
Our approach focuses on making the protein usable, measurable, and scalable enough for its intended purpose.
Glycoproteins and post-translationally complex proteins
Glycoproteins require expression systems and analytics that control post-translational quality.
A glycoprotein program can depend on glycan profile, folding, secretion, receptor interaction, half-life, uptake, immunogenicity risk, potency, or stability. The host system matters because it shapes the glycan pattern and related product attributes.
CDMO Network supports glycoprotein programs through mammalian cell culture, CHO and HEK293 systems, cell line development, clone screening, upstream condition optimization, downstream purification, glycan analysis, charge variant testing, potency assays, formulation, stability, and GMP manufacturing.
Our support includes programs where glycosylation affects biological function, receptor binding, clearance, stability, or regulatory expectations.
Glycoprotein manufacturing requires more than producing a band at the right molecular weight.
The process has to preserve the product profile that supports biological performance and quality expectations.
Recombinant antigens and diagnostic proteins
Recombinant antigens and diagnostic proteins support immunoassays, vaccine research, controls, calibrators, diagnostic reagents, infectious disease testing, antibody development, and life science tools.
These products require application-specific production. A viral antigen may need correct epitope presentation. A bacterial antigen may need solubility and low background. A diagnostic protein may need lot consistency and assay compatibility. A vaccine research antigen may need conformation and antigenicity. A calibrator protein may need assigned behavior and stability.
CDMO Network offers recombinant antigen production, viral antigen manufacturing, diagnostic protein manufacturing, assay protein supply, and research-grade or commercial reagent protein production.
Our support includes construct design, host selection, expression screening, purification, refolding, endotoxin reduction where relevant, identity testing, purity testing, binding assays, antigenicity testing, formulation, stability, aliquoting, lyophilization, and lot consistency planning.
Diagnostic and research proteins succeed when they perform in the assay, not only when they express.
The application defines the control strategy.
Protein complexes and multimeric biologics
Protein complexes and multimeric proteins require control over assembly.
These programs can include multimeric enzymes, receptor complexes, viral antigens, scaffold proteins, protein nanoparticles, VLP-related proteins, structural proteins, multichain proteins, protein assemblies, and engineered complexes.
The manufacturing challenge involves expression of the correct components, assembly state, stoichiometry, purity, aggregation, dissociation, stability, and analytical resolution. A process can produce the right subunits and still fail to create the correct assembled product.
CDMO Network supports protein complex programs through co-expression strategies, host selection, purification development, assembly analytics, SEC, mass analysis, particle methods where relevant, potency or binding assays, formulation, and stability testing.
Our support includes both research-grade complex proteins and GMP-oriented complex biologics.
The product control strategy has to define what the assembled product is, how it forms, how it is purified, and how it remains stable.
Upstream process development and scale
Recombinant protein scale requirements vary widely.
A program may need milligrams for screening, grams for research supply, kilograms for industrial use, pilot-scale material for development, GMP clinical supply, or recurring commercial production.
CDMO Network offers access to flexible production scales across transient mammalian expression, stable CHO manufacturing, microbial fermentation, yeast systems, insect-cell production, single-use bioreactors, stainless steel systems, fed-batch processes, perfusion processes, high-cell-density fermentation, and specialized expression platforms.
Our upstream support includes media development, feed strategy, induction strategy, transfection optimization, infection systems where relevant, bioreactor condition control, harvest timing, scale-down modeling, process characterization, and transfer planning.
Scale changes the process.
Oxygen transfer, mixing, heat removal, shear, host stress, proteolysis, impurity burden, glycan profile, harvest behavior, and product quality can all shift as production grows.
The route must preserve product quality while meeting the required scale.
Downstream purification and recovery
Purification determines whether the protein becomes a usable product.
Downstream support includes clarification, depth filtration, centrifugation, capture chromatography, polishing chromatography, affinity purification, ion exchange, hydrophobic interaction, mixed-mode methods, precipitation, refolding, ultrafiltration, diafiltration, concentration, buffer exchange, viral clearance where relevant, endotoxin reduction, and sterile filtration where appropriate.
CDMO Network routes purification work by protein type, impurity profile, purity target, yield requirement, quality level, and cost structure.
A therapeutic protein needs stronger impurity clearance, method control, and documentation. A diagnostic protein needs assay-compatible purity and lot consistency. An industrial protein needs cost-aware recovery. A difficult protein may need refolding, solubility control, or non-standard capture methods.
Downstream design has to remove what interferes while preserving the functional protein.
A high-yield upstream process does not solve a weak recovery strategy.
Analytical development and product characterization
Recombinant proteins need analytical methods that explain identity, purity, function, impurities, and stability.
Our support includes SEC, IEX, HIC, RP-HPLC, UPLC, CE-SDS, cIEF, SDS-PAGE, western blot where relevant, LC-MS, intact mass, reduced mass, peptide mapping, glycan analysis, charge variant analysis, aggregation testing, host-cell protein testing, residual DNA testing, residual RNA testing, endotoxin, bioburden, sterility coordination where relevant, activity assays, potency assays, binding assays, antigenicity assays, enzymatic assays, and stability-indicating methods.
The method set depends on the product’s function and use.
A therapeutic protein needs release-ready methods and regulatory CMC logic. A diagnostic protein needs assay-relevant performance testing. An enzyme needs activity and specific activity. A glycoprotein needs glycan and charge profile awareness. A protein complex needs assembly and purity assessment. A research reagent needs fit-for-use QC and lot consistency.
Analytical work creates the evidence that supports release, comparability, stability, and supply.
The testing package must answer the product’s real quality questions.
Formulation, stability, and final presentation
Recombinant proteins often fail after production if formulation receives too little attention.
Proteins can aggregate, oxidize, deamidate, clip, adsorb, precipitate, lose activity, change charge profile, or degrade during storage, freezing, thawing, drying, shipment, dilution, or final use.
CDMO Network offers formulation and stability support across liquid formulations, frozen formats, lyophilized products, high-concentration proteins, research reagent buffers, diagnostic protein formats, enzyme stabilization, sterile injectable development, vial filling, prefilled syringe support, cartridge support, and bulk commercial protein supply.
Our formulation support includes pH optimization, buffer screening, excipient selection, surfactants, stabilizers, salts, sugars, polyols, proteins, preservatives where appropriate, freeze-thaw testing, in-use stability, shipping studies, container compatibility, and long-term stability planning.
The formulation has to protect the property that matters: activity, binding, potency, antigenicity, structure, solubility, or customer-use performance.
A protein is not finished when it purifies.
It is finished when it remains usable under the conditions required by the program.
GMP manufacturing, tech transfer, and commercial supply
Recombinant protein programs need manufacturing routes that match stage and destination.
CDMO Network offers non-GMP research material, preclinical supply, GMP clinical drug substance, sterile drug product support, diagnostic-quality reagent supply, industrial protein supply, food and nutrition protein production, and commercial biologics manufacturing.
Our support includes batch planning, raw material control, cell banking or strain banking, upstream production, downstream purification, release testing, quality documentation, stability placement, fill-finish coordination, tech transfer, scale-up, method transfer, supplier qualification, quality agreements, and lifecycle planning.
The CDMOs in our Network support small custom batches, pilot development batches, clinical GMP supply, large-scale microbial fermentation, mammalian commercial production, and recurring commercial supply programs.
Tech transfer matters when the process moves between development, manufacturing, testing, fill-finish, or commercial sites. A strong transfer package preserves process knowledge, method logic, known sensitivities, raw material details, and execution assumptions.
Commercial supply requires repeatability.
The process must produce the same usable protein across lots, sites, timelines, and customer or regulatory expectations.
Niche recombinant protein formats supported
This modality group includes mainstream and highly specialized recombinant proteins.
Support extends across therapeutic proteins, glycoproteins, enzymes, recombinant enzymes, cytokines, growth factors, hormones, blood factors, plasma proteins, fusion proteins, Fc-fusions, peptides, long-acting proteins, modified proteins, PEGylated proteins, difficult-to-express proteins, secreted proteins, membrane proteins, disulfide-rich proteins, aggregation-prone proteins, protease-sensitive proteins, lysosomal enzymes, diagnostic proteins, scaffold proteins, recombinant antigens, viral antigens, protein complexes, multimeric proteins, VLP-related proteins, protein nanoparticles, receptor proteins, signaling proteins, and custom biological materials.
Each program receives a route based on expression system, molecular behavior, intended use, quality level, analytical burden, formulation need, scale, and supply model.
A single CDMO template cannot cover the entire recombinant protein field.
The protein’s biology determines the route.
Recombinante eiwitten en complexe biologics vereisen productie die expressie, vouwing, zuivering, activiteit, stabiliteit en schaalbaarheid samen beheerst. Een cytokine heeft andere eisen dan een enzym, glycoproteïne, viraal antigeen, fusie-eiwit, membraaneiwit of multimeer eiwitcomplex. CDMO Network verbindt hostselectie, procesontwikkeling, downstream recovery, analytische karakterisering, formulering, GMP-productie en commerciële levering met de specifieke functie en toepassing van het eiwit.
Industry Fit
Recombinant protein and complex biologics teams use this support when they need expression, manufacturing, testing, formulation, or supply planning for protein-based products.
This includes therapeutic protein developers, enzyme companies, cytokine and growth factor programs, diagnostic protein suppliers, vaccine antigen teams, research reagent companies, industrial biologics programs, food and nutrition protein developers, biosimilar teams, academic spinouts, and companies working with difficult or unusual protein systems.
The work supports discovery expression, feasibility batches, preclinical material, GMP drug substance, diagnostic reagent supply, industrial production, commercial manufacturing, and long-term supply planning.
Recombinant protein CDMO strategy starts with protein function, expression system, product quality target, analytical requirement, formulation risk, intended use, and scale. Those factors determine whether the program needs rapid expression, difficult-protein troubleshooting, GMP manufacturing, specialty analytics, application-specific formulation, or commercial supply.
Requirements for high-quality recombinant protein CDMO services
A robust CDMO strategy for recombinant proteins begins with comprehensive assessment of the protein’s structure, biological function, production host, intended use, critical quality attributes, analytical requirements, formulation needs, target scale, and supply model.
Comprehensive support encompasses therapeutic proteins, enzymes, cytokines, growth factors, hormones, blood factors, plasma proteins, glycoproteins, fusion proteins, peptides, modified proteins, difficult-to-express proteins, membrane proteins, recombinant antigens, diagnostic proteins, protein complexes, and industrial biologics.
Core services include host selection, construct design, expression screening, cell line or strain development and engineering, upstream process development, downstream purification, refolding, activity testing, potency assays, impurity profiling, analytical characterization, formulation and stability studies, GMP manufacturing, fill-finish coordination, technology transfer, scale-up, and commercial supply planning.
Therapeutic proteins require optimized potency, purity, stability, GMP documentation, formulation development, and regulatory CMC support. Diagnostic proteins require assay relevance, lot-to-lot consistency, formulation compatibility, and fit-for-use QC. Industrial proteins require scalable production, cost-effective recovery, activity retention, and reliable supply. Difficult-to-express proteins require tailored host-system strategies, process troubleshooting, purification flexibility, and focused formulation development.
High-quality recombinant protein CDMO services preserve the protein’s structure, function, stability, and manufacturability from initial expression through final supply.
Email our team at info@cdmonetwork.com